Suggested remit - To appraise the clinical and cost effectiveness of galcanezumab within its marketing authorisation for preventing cluster headache.
Status In progress
Process STA 2018
ID number 1212

Provisional Schedule

Expected publication 24 February 2021

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
12 December 2019 In progress, Referred: April 29 2019
12 December 2019 Following on from advice received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early April 2020. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
13 November 2018 - 11 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance